UNSPSC 51112011: Vatalanib

This classification denotes a tyrosine kinase inhibitor with the molecular formula C20H15ClN4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 5DX9U76296, chemically known as 1-phthalazinamine, n-(4-chlorophenyl)-4-(4-pyridinylmethyl)- but generally known as vatalanib, which bears US NIH Compound Identifier 151194. European Medicines Agency schedules Vatalanib in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB26999.

UNSPSC 51112011 Vatalanib is a Commodity code representing generic pharmaceutical products and over-the-counter medications that state and local governments procure through cooperative purchasing agreements and direct supply arrangements. State and local buyers use this code to source specific generic drugs and OTC items for distribution across public health facilities, hospitals, correctional institutions, and other government healthcare operations. The issuing bodies soliciting under this code include state health departments, cooperative purchasing alliances that aggregate demand across multiple states and localities, and individual counties and municipalities participating in multi-state pharmaceutical contracts. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, is a significant repeat buyer in this space, using cooperative vehicles to leverage purchasing power across participating jurisdictions in multiple states including Oregon.

Recent activity under the code centers on Oregon, Minnesota, and states participating in MMCAP's multi-state purchasing alliance. MMCAP issued an RFP (S1070000015802) on January 20, 2026 with a response deadline of March 26, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products. The procurement requires vendors to supply products through three authorized wholesalers (AmerisourceBergen Drug Corporation, Cardinal Health, and Morris & Dickson Co., LLC) and mandates cGMP certification and Drug Supply Chain Security Act compliance. Evaluation emphasizes price competitiveness (75 percent weight) alongside administrative capability such as EDI functionality and pricing format compliance. Contract awards are effective July 1, 2026, with a two-year initial term for new vendors and optional extensions at MMCAP's discretion. Vendors must maintain $5 million commercial general liability insurance and accept a 3 percent administrative fee on all contract purchases.